Literature DB >> 14993903

Targeting the checkpoint kinases: chemosensitization versus chemoprotection.

Bin-Bing S Zhou1, Jiri Bartek.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 14993903     DOI： 10.1038/nrc1296

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  138 in total

1.  Discovery of novel checkpoint kinase 1 inhibitors by virtual screening based on multiple crystal structures.

Authors:  Yan Li; Dong Joon Kim; Weiya Ma; Ronald A Lubet; Ann M Bode; Zigang Dong
Journal:  J Chem Inf Model       Date:  2011-10-12       Impact factor: 4.956

Review 2.  Chemotherapeutic approaches for targeting cell death pathways.

Authors:  M Stacey Ricci; Wei-Xing Zong
Journal:  Oncologist       Date:  2006-04

3.  Elucidating the digital control mechanism for DNA damage repair with the p53-Mdm2 system: single cell data analysis and ensemble modelling.

Authors:  Babatunde A Ogunnaike
Journal:  J R Soc Interface       Date:  2006-02-22       Impact factor: 4.118

4.  p14ARF activates a Tip60-dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress.

Authors:  Béatrice Eymin; Paule Claverie; Caroline Salon; Camille Leduc; Edwige Col; Elisabeth Brambilla; Saadi Khochbin; Sylvie Gazzeri
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

5.  p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.

Authors:  H Christian Reinhardt; Aaron S Aslanian; Jacqueline A Lees; Michael B Yaffe
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

6.  RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma.

Authors:  Kristina A Cole; Jonathan Huggins; Michael Laquaglia; Chase E Hulderman; Mike R Russell; Kristopher Bosse; Sharon J Diskin; Edward F Attiyeh; Rachel Sennett; Geoffrey Norris; Marci Laudenslager; Andrew C Wood; Patrick A Mayes; Jayanti Jagannathan; Cynthia Winter; Yael P Mosse; John M Maris
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-02       Impact factor: 11.205

7.  Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner.

Authors:  Oren Gilad; Barzin Y Nabet; Ryan L Ragland; David W Schoppy; Kevin D Smith; Amy C Durham; Eric J Brown
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

Review 8.  Cell cycle control as a basis for cancer chemoprevention through dietary agents.

Authors:  Syed Musthapa Meeran; Santosh Kumar Katiyar
Journal:  Front Biosci       Date:  2008-01-01

Review 9.  Integrating S-phase checkpoint signaling with trans-lesion synthesis of bulky DNA adducts.

Authors:  Laura R Barkley; Haruo Ohmori; Cyrus Vaziri
Journal:  Cell Biochem Biophys       Date:  2007       Impact factor: 2.194

10.  Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.

Authors:  Elda Grabocka; Yuliya Pylayeva-Gupta; Mathew J K Jones; Veronica Lubkov; Eyoel Yemanaberhan; Laura Taylor; Hao Hsuan Jeng; Dafna Bar-Sagi
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.